Display Settings:

Format

Send to:

Choose Destination
    Trends Endocrinol Metab. 1999 Dec;10(1):9-13.

    Mechanisms by which Thiazolidinediones Enhance Insulin Action.

    Source

    Departments of Pharmacology and Medicine, University of Pennsylvania Medical Center, Philadelphia, PA 19104, USA.

    Abstract

    Thiazolidinediones (TZDs) are an exciting new class of insulin-sensitizing drugs being used currently for the treatment of non-insulin-dependent diabetes mellitus. The molecular target of these compounds is thought to be the nuclear hormone receptor, peroxisome proliferator-activated receptor gamma (PPARgamma). PPARgamma is expressed predominantly in adipose tissue, yet a major site of TZD-responsive glucose disposal is skeletal muscle. Potential explanations for this paradox are discussed in this review.

    PMID:
    10322388
    [PubMed - as supplied by publisher]

      Supplemental Content

      Icon for Elsevier Science

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk